Overview KLOW is a four-peptide blend developed in research-supply settings that combines three peptides — GHK-Cu (50 mg), BPC-157 (10 mg), and TB-500 (10 mg), collectively the "GLOW" blend — with the α-MSH(11–13) tripeptide KPV (10 mg). Each component engages a separate mechanism. GHK-Cu functions as a copper-delivery vehicle and broad gene modulator — Pickart's group has reported >50% expression changes in roughly 31% of the human genome, with ECM synthesis (collagen I/I

How does KLOW work? What is its mechanism of action?

Mechanism of Action — Per Component GHK-Cu (50 mg) — Copper Delivery & Gene Modulation GHK-Cu (Gly-His-Lys-Cu²⁺, ~401.9 Da) is a redox-silenced copper-tripeptide complex that delivers Cu(II) intracellularly without driving Fenton-reaction toxicity, supplying copper to enzymes such as lysyl oxidase (collagen crosslinking) and Cu/Zn-SOD (antioxidant defense).[1] Connectivity Map analysis links GHK-Cu to >50% expression changes in ~31% of human genes, biasing toward ECM synthesis (collagen I

What are the research applications of KLOW?

Research Applications KLOW combines four peptides whose individual literatures span tissue repair, angiogenesis, gene modulation, and anti-inflammatory signaling. Component-level research areas: Inflammatory Bowel Disease Models — KPV has been evaluated in murine DSS-colitis and TNBS-colitis models for PepT1-mediated reduction in NF-κB transcription.[13][14] Wound Healing & Skin Research — GHK-Cu (collagen/elastin synthesis), BPC-157 (granulation tissue), TB-500 (keratinocyte migration), KPV

What does the research summary say about KLOW?

Preclinical Research Summary (Component-Level) No peer-reviewed studies have evaluated the KLOW 50/10/10/10 blend as a co-administered formulation. Component-level research is summarized below; for full data see the dedicated GHK-Cu, BPC-157, TB-500, and KPV entries. ComponentRepresentative StudyKey Finding GHK-CuPickart & Margolina (2018)Modulates >4,000 genes (gene-expression data review) BPC-157Hsieh et al. (2017)129–152% increased angiogenesis via VEGFR2-Akt-eNOS TB-500Philp et al. (2

How should KLOW be stored?

Lyophilized blend at −20°C (12–24 months). Avoid freeze-thaw cycles; protect from light and moisture.

Storing KLOW: Best Practices

14 PubMed CitationsExpert ReviewedLast Reviewed: April 2026

Recommended Laboratory Storage Conditions — KLOW Blend (80 mg)

Lyophilized Powder: Store at −20°C (−4°F) for long-term stability (12–24 months). The blend stability window is constrained by the most thermolabile component — for KLOW this is TB-500 and KPV. BPC-157 is unusually stable at room temperature, and GHK-Cu is robust below 25°C, but the blend should be handled to the strictest member's specification. Use desiccant; protect from direct light.

Handling: Standard aseptic technique with PPE (gloves, lab coat). Avoid repeated freeze-thaw cycles — peptide blends with a copper-complex component are particularly sensitive to oxidative degradation under thermal cycling.

Compatibility note: All four peptides are pre-co-lyophilized at point of manufacture. Do not split or partition the powder physically; the homogeneity of the 50/10/10/10 ratio is only guaranteed for the entire vial contents.

Editorial Research Note

“Preclinical Research Summary (Component-Level) No peer-reviewed studies have evaluated the KLOW 50/10/10/10 blend as a co-administered formulation.”

Pure U.S. Peptides Research Standards TeamInternal editorial group summarising published peptide research for an audience of qualified independent investigators.

References

Related research

The Freedom Stack — Storage & handling The Grand Slam Bundle — Storage & handling The Long Shot — Storage & handling

Browse all research guides in the Peptide Research Library →

Want the complete research review?

Browse the Peptide Research Library→